Skip to main content
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALDX ISIN · US01438T1060 LEI · 529900HGKY864E4Y9014 US Manufacturing
Filings indexed 621 across all filing types
Latest filing 2025-08-15 Director's Dealing
Country US United States of America
Listing US ALDX

About Aldeyra Therapeutics, Inc.

https://www.aldeyra.com/

Aldeyra Therapeutics is a biotechnology company developing medications for immune-mediated diseases. The company's therapeutic approach involves modulating immunological systems rather than inhibiting or activating single protein targets, with the goal of optimizing multiple pathways while minimizing toxicity. Its portfolio of product candidates targets inflammatory cells associated with both ocular and systemic ailments. Aldeyra has investigational therapies in late-stage clinical development for conditions such as dry eye disease and allergic conjunctivitis, aiming to address medical needs not adequately met by existing treatments.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-08-15 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
4
Director's Dealing
2025-08-14 English
Regulatory Filings 2025
Regulatory Filings
2025-08-12 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-07 English
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or other material information that occurs between periodic reports. The text includes a press release about the FDA accepting for review a resubmitted New Drug Application and assigns a PDUFA target action date. The document is short (4173 characters) and primarily serves as an announcement of this event, including a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document is not an annual or quarterly report, nor a management discussion or earnings release. It is a regulatory filing to inform the market of a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-07-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.